Artiva Biotherapeutics, Inc.ARTVNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank50
3Y CAGR-33.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-33.8%/yr
Annual compound
Percentile
P50
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 17.81% |
| 2024 | 23.67% |
| 2023 | -33.04% |
| 2022 | 61.50% |
| 2021 | 190.65% |
| 2020 | 0.00% |
| 2019 | 0.00% |